«‹1234567»Seite
7 articles with references, page 1 of 7

Review article

Metastases in the Absence of a Primary Tumor: Advances in the Diagnosis and Treatment of CUP Syndrome

Dtsch Arztebl Int 2008; 105(43): 733-40; DOI: 10.3238/arztebl.2008.0733

Neben, K; Hübner, G; Folprecht, G; Jäger, D; Krämer, A

1. Califano J, Westra WH, Koch W et al.: Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin. J Natl Cancer Inst 1999; 91: 599–604. MEDLINE
2. Varadhachary GR, Abbruzzese JL, Lenzi R: Diagnostic strategies for unknown primary cancer. Cancer 2004; 100: 1776–85. MEDLINE
3. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN: Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 1995; 13: 2094–103. MEDLINE
4. Greco FA, Burris HA, Litchy S et al.: Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol 2002; 20: 1651–6. MEDLINE
5. Culine S, Lortholary A, Voigt JJ et al.: Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 2003; 21: 3479–82. MEDLINE
6. Hübner G, Steinbach S, Kohne CH et al.: Paclitaxel/carboplatin versus gemcitabine/vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary (CUP) – a randomized prospective phase-II-trial. Proc Am Soc Clin Oncol 2005; 23: 330 (Abstract 4089).
7. Palmeri S, Lorusso V, Palmeri L et al.: Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site: results of an Italian multicenter, randomized, phase II study. Cancer 2006; 107: 2898–905. MEDLINE
8. Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL: Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 1999; 5: 3403–10. MEDLINE
9. Bugat R, Bataillard A, Lesimple T et al.: Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer 2003; 89 (Suppl 1): 59–66. MEDLINE
10. Hainsworth JD, Spigel DR, Litchy S, Greco FA: Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 2006; 24: 3548–54. MEDLINE
11. Kaufmann O, Fietze E, Dietel M: Immunohistochemical diagnosis in cancer metastasis of unknown primary tumor. Pathologie 2002; 23: 183–97. MEDLINE
12. Hossfeld DK, Wittekind C: Metastasen bei unbekanntem Primärtumor: Das CUP-Syndrom. Dtsch Arztebl 2005; 102 (13): A 904–7. VOLLTEXT
13. Sève P, Billotey C, Broussolle C, Dumontet C, Mackey JR: The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 2007; 109: 292–9. MEDLINE
14. Motzer RJ, Rodriguez E, Reuter VE, Bosl GJ, Mazumdar M, Chaganti RS: Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. J Clin Oncol 1995; 13: 274–82. MEDLINE
15. Tothill RW, Kowalczyk A, Rischin D et al.: An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 2005; 65: 4031–40. MEDLINE
16. Woods RL, Fox RM, Tattersall MH, Levi JA, Brodie GN: Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens. N Engl J Med 1980; 303: 87–9. MEDLINE
17. Milliken ST, Tattersall MH, Woods RL et al.: Metastatic adenocarcinoma of unknown primary site: a randomized study of two combination chemotherapy regimens. Eur J Cancer Clin Oncol 1987; 23: 1645–8. MEDLINE
18. Eagan RT, Therneau TM, Rubin J, Long HJ, Schutt AJ: Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site: a randomized trial. Am J Clin Oncol 1987; 10: 82–5. MEDLINE
19. Falkson CI, Cohen GL: Mitomycin C, epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary origin. Oncology 1998; 55: 116–21. MEDLINE
20. Assersohn L, Norman AR, Cunningham D et al.: A randomized study of protracted venous infusion of 5-fluorouracil (5- FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary. Eu J Cancer 2003; 39: 1121–8. MEDLINE
21. Dowell JE, Garrett AM, Shyr Y, Johnson DH, Hande KR: A randomized phase II trial in patients with carcinoma of an unknown primary site. Cancer 2001; 91: 592–7. MEDLINE
22. Briasoulis E, Kalofonos H, Bafaloukos D et al.: Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 2000; 18: 3101–7. MEDLINE
23. Greco FA, Rodriguez GI, Shaffer DW et al.: Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial. Oncologist 2004; 9: 644–52. MEDLINE
24. Massard C, Voigt JJ, Laplanche A et al.: Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? Br J Cancer 2007; 97: 857–61. MEDLINE
25. Hainsworth JD, Spigel DR, Farley C, Thompson DS, Shipley DL, Greco FA; Minnie Pearl Cancer Research Network: Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol 2007; 25: 1747–52. MEDLINE
e1. Le Chevalier T, Cvitkovic E, Caille P et al.: Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med 1988; 148: 2035–9. MEDLINE
e2. Altman E, Cadman E: An analysis of 1539 patients with cancer of unknown primary site. Cancer 1986; 57: 120–4. MEDLINE
e3. van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF: Epidemiology of unknown primary tumors; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984–1992. Eur J Cancer 2002; 38: 409–13. MEDLINE
e4. Levi F, Te VC, Erler G, Randimbison L, La Vecchia C: Epidemiology of unknown primary tumors. Eur J Cancer 2002; 38: 1810–2. MEDLINE
e5. Gutzeit A, Antoch G, Kühl H et al.: Unknown primary tumors: detection with dual-modality PET/CT – initial experience. Radiology 2005; 234: 227–34. MEDLINE
e6. Nanni C, Rubello D, Castellucci P et al.: Role of 18F-FDG PET-CT imaging for the detection of an unknown primary tumor: preliminary results in 21 patients. Eur J Nucl Med Mol Imaging 2005; 32: 589–92. MEDLINE
e7. Pelosi E, Pennone M, Deandreis D, Douroukas A, Mancini M, Bisi G: Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Q J Nucl Med Mol Imaging 2006; 50: 15–22. MEDLINE
e8. Hedley DW, Leary JA, Kirsten F: Metastatic adenocarcinoma of unknown primary site: abnormalities of cellular DNA content and survival. Eur J Cancer Clin Oncol 1985; 21: 185–9. MEDLINE
e9. Pantou D, Tsarouha H, Papadopoulou A et al.: Cytogenetic profile of unknown primary tumors: clues for their pathogenesis and clinical management. Neoplasia 2003; 5: 23–31.
e10. Petersen I, Hidalgo A, Petersen S et al.: Chromosomal imbalances in brain metastases of solid tumors. Brain Pathol 2000; 10: 395–401.
e11. Bar-Eli M, Abbruzzese JL, Lee-Jackson D, Frost P: p53 gene mutation spectrum in human unknown primary tumors. Anticancer Res 1993; 13: 1619–23.
e12. Ma XJ, Patel R, Wang X et al.: Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med 2006; 130: 465–73.
e13. Rosenfeld N, Aharonov R, Meiri E et al.: Micro-RNAs accurately identify cancer tissue origin. Nat Biotechnol 2008; 26: 462–9.
e14. Bridgewater J, van Laar R, Floore A, Van'T Veer L: Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. Br J Cancer 2008; 98: 1425–30.
e15. Culine S, Fabbro M, Ychou M, Romieu G, Cupissol D, Pujol H: Chemotherapy in carcinomas of unknown primary site: a high-dose intensity policy. Ann Oncol 1999; 10: 569–75.
e16. Culine S, Kramar A, Saghatchian M et al.: Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002; 20: 4679–83.
e17. Hainsworth JD, Lennington WJ, Greco FA: Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. J Clin Oncol 2000; 18: 632–5.
e18. Morawietz L, Dietel M: Der unbekannte Primarius – eine diagnostische Herausforderung. Im Focus Onkologie 2007; 5: 59–64.